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Recently two overviews have appeared on cancer risks and surveillance in Beckwith-Wiedemann 
syndrome (BWS) [Maas et al., 2016; Mussa et al., 2016]. This has prompted us as an international group 
of researchers to initiate a similar study of “isolated hemihyperplasia” (IHH; OMIM 23500), as IHH 
shares with BWS the body asymmetry and risk to develop cancer [Clericuzio and Martin, 2009].  
However, a major problem in designing this study is the definition and various terms that are 
used. The most commonly used terms are “isolated hemihyperplasia” and “isolated hemihypertrophy”, 
usually defined as proposed by Clericuzio and Martin [2009]: “asymmetric regional body overgrowth 
because of an underlying abnormality of cell proliferation in individuals without any other underlying 
diagnosis” to which the authors added as comments “there are no widely accepted criteria for defining 
IHH as distinct from normal growth variation in children, and therefore the pragmatic case definition is 
that IHH should be apparent ‘from the end of the bed’.”  
We propose here to designate a novel term for this finding, formatted in accordance with the 
standards set by the Elements of Morphology [Allanson et al., 2009]. 
Lateralized Overgrowth 
Definition: Significant increase in the length and/or girth of most or all of one side of the body compared 
to its contralateral side. 
Synonyms: Segmental overgrowth 
Replaces: Hemihyperplasia; Hemihypertrophy 
 
Comments:  
1.  We replaced the term ‘hemi” as it is seemingly indicating that the overgrowth should be present at the 
same half of the body. However, the overgrowth can also be present in body parts that differ in body 
laterality. 
2.  The use of the terms “hyperplasia” or “hypertrophy” are problematic as this is a histologic description 
while histological proof is only rarely available. The term “overgrowth” indicates the same phenomenon 
without suggesting the histologic specificity. Furthermore, it is usually not known whether the difference 
in size between the left and right body half is caused by an overdevelopment of one body half or instead 
underdevelopment of the other body half, or a combination of these. For example, patients with 
asymmetry may be proven to carry H19 hypomethylation, which is mostly associated with undergrowth 
[Russo et al., 2016]. We acknowledge that typically the sign that is clinically apparent (‘from the end of 
the bed’) is the overdevelopment, and that underdevelopment may or may not be present. The terms 
“unilateral overgrowth” or “lateralized overgrowth” describe better what can be visualized during 
physical exam. We prefer the term ‘lateralized’ as the term ‘unilateral’ seemingly indicates the 
overgrowth is present on one side while overgrowth can be crossed or restricted to different sides of the 
body. We also considered the term “asymmetrical overgrowth” but then overgrowth in the upper versus 
the lower body segment would also fulfill this description, and entities such as various forms of 
lipodystrophy would fulfill the description as well while these constitute a different type of disorders. 
3.  The definition does not specify the component(s) of the increased size (bone, connective tissue, blood 
vessels, muscles, etc.) as any combination can occur. It should however exclude edema as this is not 
overgrowth. 
4.  Overgrowth of an organ (including asymmetry of kidneys) may or may not be present and is not a 
prerequisite for the finding. 
5.  We refrain deliberately from defining the term ‘significant’ which we use in the definition. Our 
clinical experience suggests that determining a degree of asymmetry between left and right side of the 
body by inspection, palpation or measurements is not sufficiently reliable. Additionally, the previous 
definition ‘from the end of the bed’ may not account for clinically apparent but more subtle cases. We 
estimate that in clinical practice differences in length or girth of 10% can usually be determined, and 
experienced physicians may even determine smaller differences. However, we prefer not to use subjective 
criteria in the definition that are dependent on the experience of the physician. Objective techniques such 
as measurements using 3D imaging technology and DEXA scanning may be more useful and need to be 
studied in more detail [Waelchli et al., 2015; Bazzocchi et al., 2016; Ng et al., 2016]. Techniques that 
allow the combination of soft and skeletal tissue measurements may prove to be especially useful 
[Ibrahim et al., 2016]. As physiological variations in symmetry exist between populations and body parts 
if determined by direct measurements of bones [Auerbach and Ruff, 2006], normal values using such 
techniques need to be developed as well. Until results of such studies are available, we propose to leave it 
to the discretion of the examining clinician to decide if a difference in size between left and right side of 
(or part of) the body is significant.  
 
Using this definition of lateral overgrowth, we subsequently redefine the diagnosis of “isolated (or non-
syndromic) hemihyperplasia” and “isolated (or non-syndromic) hemihypertrophy” as “isolated 
lateralized overgrowth.” Isolated lateralized overgrowth is lateralized overgrowth in the absence of a 
recognizable pattern of major or minor malformations, dysplasias, or morphologic variants [Hennekam et 
al., 2013]. We recognize that isolated lateralized overgrowth is likely genetically heterogeneous and may 
be part of currently unrecognized patterns of malformation. Subdivision into separate entities may 
become possible if sufficiently large numbers of affected individuals are carefully studied clinically and 
molecularly, as was accomplished with Proteus syndrome (PMID 16883308), CLOVES syndrome (PMID 
17963221), and ‘Hemihyperplasia’ with multiple lipomatosis (HHML, PMID 9781913). These entities 
were split based on careful phenotyping before their etiologic basis was discovered. This may allow 
separation of groups of affected individuals based on their molecular background or based on a pattern of 
concomitant subtle features that becomes evident. Such subdivisions may also indicate differences in 
nature, age of onset, reaction to various management schemes, prognosis, and risks for cancer in the 
affected individuals and their families, similar to what the recent studies in BWS have shown [Maas et al., 
2016; Mussa et al., 2016]. 
In summary, this definition of lateralized overgrowth is a necessary first step towards 
characterization and determination of diagnostic subdivisions within the category of isolated lateralized 
overgrowth to thereby determine additional related clinical features and molecular etiology.  
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Figure 1. A series of examples of individuals with isolated lateralized overgrowth.  
